Orchestra BioMed Holdings (OBIO) Return on Sales (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Return on Sales of 2.25% for Q1 2026, down 203.0% year-over-year from 2.18% in Q1 2025, and down 108933.57% quarter-over-quarter from 0.0% in Q4 2025.
Orchestra BioMed Holdings (OBIO) Return on Sales (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Return on Sales for 5 consecutive years, with 2.25% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Sales fell 203.0% year-over-year to 2.25%; the TTM figure through Mar 2026 stood at 0.02% (up 25.0% YoY), while the FY2025 annual figure was 0.05%, up 55.0% from the prior year.
- Return on Sales retreated to 2.25% in Q1 2026 per OBIO's latest filing, from 0.0% in the prior quarter.
- Across five years, Return on Sales topped out at 0.0% in Q4 2025 and bottomed at 2.25% in Q1 2026.
- Historically, Return on Sales has averaged 0.36% across 5 years, with a median of 0.22% in 2025.
- Annual changes were most pronounced in 2025 — Return on Sales soared 64 bps — and 2026, when it plunged 203 bps.
- Orchestra BioMed Holdings' Return on Sales stood at 0.09% in 2022, then slumped by 421 bps to 0.48% in 2023, then tumbled by 34 bps to 0.64% in 2024, then surged by 100 bps to 0.0% in 2025, then tumbled by 108934 bps to 2.25% in 2026.
- Business Quant data shows OBIO's Return on Sales at 2.25% in Q1 2026, 0.0% in Q4 2025, and 0.24% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 0.00% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.00% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.00% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.00% |
| 10 | Orchestra BioMed Holdings | 265.06 Mn | 80.63 Mn | 63,000.00 | -2.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.87% |
| Mar 31, 2026 | -2.25% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | -0.24% |
| Jun 30, 2025 | -0.26% |
| Mar 31, 2025 | -0.22% |
| Dec 31, 2024 | -0.64% |
| Sep 30, 2024 | -0.18% |
| Jun 30, 2024 | -0.32% |
| Mar 31, 2024 | -0.25% |
| Dec 31, 2023 | -0.48% |
| Sep 30, 2023 | -0.53% |
| Jun 30, 2023 | -0.19% |
| Mar 31, 2023 | -0.10% |
| Dec 31, 2022 | -0.09% |
| Sep 30, 2022 | -0.09% |
| Jun 30, 2022 | -0.20% |
| Mar 31, 2022 | -0.06% |